|
FY2025
12 months to Sep 28, 2025
|
FY2024
12 months to Sep 29, 2024
|
FY2023
12 months to Oct 1, 2023
|
FY2022
12 months to Oct 2, 2022
|
FY2021
12 months to Oct 3, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Amortization of stock-based awards | |||||
| Deferred income taxes | |||||
| Provision for losses on accounts receivables | |||||
| Fair value adjustments to contingent consideration | |||||
| Right-of-use operating lease asset impairment | |||||
| Fair value adjustment to foreign currency forward contract | |||||
| Acquisition and integration expenses | |||||
| Other non-cash items | |||||
| Changes in operating assets and liabilities, net of effects of business acquisitions and divestitures: | |||||
| Accounts receivable and contract assets | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued compensation | |||||
| Contract liabilities | |||||
| Cash settled contingent earn-out liability | |||||
| Income taxes receivable/payable | |||||
| Other liabilities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Payments for business acquisitions, net of cash acquired | |||||
| Settlement of foreign currency forward contract | |||||
| Capital expenditures | |||||
| Proceeds from sales of assets | |||||
| Proceeds from company-owned life insurance policies | |||||
| Proceeds from divested business, net | |||||
| Proceeds from loan repayment from divested business | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from borrowings | |||||
| Repayments on long-term debt | |||||
| Proceeds from issuance of convertible notes | |||||
| Payments of debt issuance costs | |||||
| Capped call transactions | |||||
| Repurchases of common stock | |||||
| Shares repurchased for tax withholdings on share-based awards | |||||
| Payments of contingent earn-out liabilities | |||||
| Stock options exercised | |||||
| Bank overdrafts | |||||
| Dividends paid | |||||
| Principal payments on finance leases | |||||
| Net cash (used in) provided by financing activities | |||||
| Effect of exchange rate changes on cash and cash equivalents | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents at end of year | |||||
| Supplemental information: | |||||
| Cash paid during the year for: | |||||
| Interest | |||||
| Income taxes, net of refunds received of $17.2 million, $4.2 million and $2.2 million | |||||
| Non-cash financing activities: | |||||
| Excise taxes accrued but not paid | |||||
| Reconciliation of cash and cash equivalents: | |||||
| Cash and cash equivalents | |||||
| Cash and cash equivalents included in assets held-for-sale | |||||
Loading...